DNA-Guided immunotherapy trial aims to match drug to tumor
NCT ID NCT04273061
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis can help select who benefits most.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (TECENTRIQ), an immunotherapy drug given by IV every 3 weeks
What this could lead to
If successful, this could show that analyzing a tumor's DNA can predict which patients will benefit from atezolizumab, leading to more personalized cancer treatment.
What could go wrong
This is an early Phase 2 trial with small groups per cancer type, so results may not apply broadly. Not all participants will respond, and side effects from immunotherapy can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BC Cancer
RECRUITINGVancouver, British Columbia, V5Z 4E6, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Health Network / Princess Margaret Cancer Centre
WITHDRAWNToronto, Ontario, M5G 2M9, Canada